Biggest News Aggregation in the World
๐Ÿ“ฐ Upcoming Launch News

Upcoming Launch News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Upcoming Launch. Real-time updates on events, politics, business and more.

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry

AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a biosimilar of blockbuster drug Humira (adalimumab), for rheumatoid arthritis. The company plans to launch Yusimry in July 2023 with a list price of $995 per carton (2 x 40 mg/0.8 mL autoinjectors), the lowest price announced to date of any adalimumab offering in the U.S. With Humira currently priced at $6,9
United States Coherus Biosciences Coherus Biosciences Inc Abbvie Inc Mark Cuban Cost Plus Drug Company Delaware Court
Source: yahoo.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science